Unveiling EIF5A2: A multifaceted player in cellular regulation, tumorigenesis and drug resistance

IF 4.7 3区 医学 Q1 PHARMACOLOGY & PHARMACY European journal of pharmacology Pub Date : 2025-04-05 DOI:10.1016/j.ejphar.2025.177596
Xifeng Xiong , Yanli Du , Peng Liu , Xinye Li , Xudong Lai , Haixiong Miao , Bo Ning
{"title":"Unveiling EIF5A2: A multifaceted player in cellular regulation, tumorigenesis and drug resistance","authors":"Xifeng Xiong ,&nbsp;Yanli Du ,&nbsp;Peng Liu ,&nbsp;Xinye Li ,&nbsp;Xudong Lai ,&nbsp;Haixiong Miao ,&nbsp;Bo Ning","doi":"10.1016/j.ejphar.2025.177596","DOIUrl":null,"url":null,"abstract":"<div><div>The eukaryotic initiation factor 5A2 gene (EIF5A2) is a highly conserved and multifunctional gene that significantly influences various cellular processes, including translation elongation, RNA binding, ribosome binding, protein binding and post-translational modifications. Overexpression of EIF5A2 is frequently observed in multiple cancers, where it functions as an oncoprotein. Additionally, EIF5A2 is implicated in drug resistance through the regulation of various molecular pathways. In the review, we describe the structure and functions of EIF5A2 in normal cells and its role in tumorigenesis. We also elucidate the molecular mechanisms associated with EIF5A2 in the context of tumorigenesis and drug resistance. We propose that the biological roles of EIF5A2 in regulating diverse cellular processes and tumorigenesis are clinically significant and warrant further investigation.</div></div>","PeriodicalId":12004,"journal":{"name":"European journal of pharmacology","volume":"997 ","pages":"Article 177596"},"PeriodicalIF":4.7000,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0014299925003504","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The eukaryotic initiation factor 5A2 gene (EIF5A2) is a highly conserved and multifunctional gene that significantly influences various cellular processes, including translation elongation, RNA binding, ribosome binding, protein binding and post-translational modifications. Overexpression of EIF5A2 is frequently observed in multiple cancers, where it functions as an oncoprotein. Additionally, EIF5A2 is implicated in drug resistance through the regulation of various molecular pathways. In the review, we describe the structure and functions of EIF5A2 in normal cells and its role in tumorigenesis. We also elucidate the molecular mechanisms associated with EIF5A2 in the context of tumorigenesis and drug resistance. We propose that the biological roles of EIF5A2 in regulating diverse cellular processes and tumorigenesis are clinically significant and warrant further investigation.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
揭示EIF5A2:细胞调控、肿瘤发生和耐药的多层面参与者。
真核起始因子5A2基因(EIF5A2)是一个高度保守的多功能基因,显著影响多种细胞过程,包括翻译延伸、RNA结合、核糖体结合、蛋白质结合和翻译后修饰。在多种癌症中经常观察到EIF5A2的过表达,其中它作为癌蛋白起作用。此外,EIF5A2通过调节多种分子途径参与耐药。本文综述了EIF5A2在正常细胞中的结构和功能及其在肿瘤发生中的作用。我们还阐明了EIF5A2在肿瘤发生和耐药过程中的相关分子机制。我们认为EIF5A2在调节多种细胞过程和肿瘤发生中的生物学作用具有临床意义,值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.00
自引率
0.00%
发文量
572
审稿时长
34 days
期刊介绍: The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems. The scope includes: Behavioural pharmacology Neuropharmacology and analgesia Cardiovascular pharmacology Pulmonary, gastrointestinal and urogenital pharmacology Endocrine pharmacology Immunopharmacology and inflammation Molecular and cellular pharmacology Regenerative pharmacology Biologicals and biotherapeutics Translational pharmacology Nutriceutical pharmacology.
期刊最新文献
Corrigendum to "Synergistic anticancer effects of doxorubicin in combination with tilorone in breast cancer" [European J. Pharmacol. 1008 (2025) 178249]. Editorial Board SIRT1-mediated YAP deacetylation suppresses myocardial hypertrophy in diabetic cardiomyopathy. Additive effect of leptin and palm-LEAP2(1-14) ameliorates obesity-induced metabolic stress in ob/ob mice. Lactoferrin ameliorates social isolation-induced cognitive decline by modulating mitochondrial function and ferroptosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1